NeuroSense announced further data from its PARADIGM Phase 2b study. 1 The new data was derived from a 12-month analysis of ...

Robert A. Michael has assumed the role of CEO at AbbVie. 1 He has replaced Richard A. Gonzalez, who stepped down from the ...

Reportedly, the liquid formulation of Tepylute eliminates the need for complex and time-consuming reconstitution, providing ...

Approval of both NRX-101 and NRX-100 could potentially yield more than $150 in revenue per NRXP share in the near term, ...

How pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by ...

After years of collaborating with hospitals, Magnolia Medical has launched a new digital platform designed to prevent sepsis ...

In an interview with Pharm Exec Associate Editor Don Tracy, Leonard Mazur, Co-founder, CEO, Citius Pharmaceuticals, offers an update on the recently accepted Biologics License Application for Lymphir ...

Approval of Epkinly was based on results from the Phase I/II EPCORE trial in patients with relapsed or refractory follicular ...

Ohtuvayre is the first inhaled product with a novel mechanism of action for chronic obstructive pulmonary disease to be ...

Ty Wiggins, PhD, is the global lead of Russell Reynolds Associates’ CEO & Executive Transition Practice. Working for an ...

Kenneth L. Kring is a Senior Client Partner in Korn Ferry's Philadelphia office and co-managing director of the Global ...

Investment is expected to fund a new fill and finish manufacturing facility to enhance production of injectable treatments ...